Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: J Immunother. 2013 Oct;36(8):10.1097/CJI.0b013e3182a80237. doi: 10.1097/CJI.0b013e3182a80237

Figure 3.

Figure 3

A. Waterfall plot of best overall radiologic response to vaccine. Immunity assessed by IFN-γ ELISPOT. Of 24 total, 3 were non-evaluable for RECIST due to lung cancer death (n = 2) or missing evaluation (n =1). * PD due to unequivocal progression of malignant pleural effusion.

B. Participants who met pre-specified immune response criteria had non-statistically significant trend towards more favorable radiologic response. SD: Stable disease, PD: Progressive disease. RECIST v 1.0. † p = 0.10 (1-tailed χ2).